Pharmacokinetic considerations on Orgaran (Org 10172) therapy.

Area of Science:

• Pharmacology
• Biochemistry

Background:

• Orgaran (Org 10172) is a complex mixture with anticoagulant properties.
• Understanding its pharmacokinetic profile is crucial for optimizing therapeutic use.

Purpose of the Study:

• To investigate the pharmacokinetics of Orgaran by monitoring anti-Xa, anti-IIa, and IIa-generation-inhibiting (IIaGI) activities.
• To compare Orgaran's pharmacokinetics with other low molecular weight heparinoids.
• To assess the bioavailability and elimination routes of Orgaran.

Main Methods:

• Monitoring plasma anti-Xa, anti-IIa, and IIaGI activities.
• Measuring No-affinity glycosaminoglyc(uron)an (NoA-GAG) fraction concentrations.
• Comparative intravenous administration studies with other heparinoids.
• Subcutaneous administration studies to determine bioavailability.

Main Results:

• Orgaran shows distinct pharmacokinetic profiles for different activities, with a long anti-Xa elimination half-life (24.5 h) but shorter anti-IIa (4.3 h) and IIaGI (6.7 h) half-lives.
• Subcutaneous absorption of Orgaran is nearly 100%, significantly higher than heparin.
• Orgaran's anti-Xa and IIaGI half-lives are longer compared to Fragmin, Fraxiparine, and Clexane.
• Renal excretion accounts for approximately 50% of anti-Xa activity clearance.

Conclusions:

• The varied elimination rates of Orgaran components necessitate twice-daily dosing for effective thrombosis prophylaxis.
• The high bioavailability via subcutaneous administration makes it a reliable route.
• Dose reduction in severe renal failure is recommended due to significant renal excretion.
• Orgaran's pharmacokinetics are relatively insensitive to hepatic function changes.